1. Prof Matt Smalley, Director
Breast Cancer Research at the European Cancer Stem Cell Research Institute
Prof Matt Smalley, Director
Dr Richard Clarkson
BCRA visit, 2nd May 2019

2. In vitro and in vivo (cancer) stem cell model systems
Therapeutic interventions and patient benefit
Pancreas
Prostate
Breast
Intestine
Blood
Brain
Stomach

3. Tumour heterogeneity in breast cancer
Smalley: Targeted treatments for breast cancers with different biology (influenced by early events in development of disease)
Clarkson: Anti-cancer stem cell therapies for breast cancers to reduce resistance to standard of care and block metastasis

4. ER- PR- HER- / Basal-like (10%)
Three key clinical groups in breast cancer
ER+ PR+
Luminal-like
(70%)
ER- PR- HER- / Basal-like (10%)
HER2 / ERBB2 amplified
(20%)
Anti-hormonal therapies (e.g. Tam; Arimidex)
Herceptin or other anti-HER2 therapies

5. LYN kinase A molecular switch which when ‘on’ keeps cells alive
In BRCA1-associated TNBC, LYN is active at high levels and cannot be switched off by the cell

7. New grant: Is LYN required for BRCA1 breast cancer to form?

8. Preliminary study: Using mouse models to decipher tumour heterogeneity

9. Preliminary study: Cross-talk between normal and tumour cells